Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;202(3):504-516.
doi: 10.1111/bjh.18932. Epub 2023 Jun 22.

Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration

Yohei Funakoshi  1 , Kimikazu Yakushijin  1 , Goh Ohji  2 , Takaji Matsutani  3 , Wataru Hojo  4 , Hironori Sakai  4 , Sakuya Matsumoto  1 , Marika Watanabe  1 , Akihito Kitao  1 , Yasuyuki Saito  5 , Shinichiro Kawamoto  6 , Katsuya Yamamoto  1 , Taiji Koyama  1 , Yoshiaki Nagatani  1 , Shiro Kimbara  1 , Yoshinori Imamura  1 , Naomi Kiyota  1   7 , Mitsuhiro Ito  8 , Hironobu Minami  1   7
Affiliations

Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration

Yohei Funakoshi et al. Br J Haematol. 2023 Aug.

Abstract

The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.

Keywords: B-cell receptor repertoire; haematopoietic stem cell transplantation; mRNA SARS-CoV-2 vaccination; tixagevimab/cilgavimab.

PubMed Disclaimer

References

REFERENCES

    1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92.
    1. Xhaard A, Xhaard C, D'Aveni M, Salvator H, Chabi ML, Berceanu A, et al. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. Br J Haematol. 2021;192(5):e121-4.
    1. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138(14):1278-81.
    1. Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, et al. The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation. Vaccines (Basel). 2022;10(2):158.
    1. Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, et al. Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody. Int J Hematol. 2022;115(1):7-10.

Publication types

LinkOut - more resources